Status and phase
Conditions
Treatments
About
Background:
Objectives:
Eligibility:
Design:
Full description
Background:
Objectives:
Eligibility:
Study Design:
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Patients must have one of the following histologic diagnoses:
-Patients must have Burkitt Lymphoma. Effective with Amendment J (version date: 06/24/2014), the following histologies were removed as the maximum number allowed for these sub-groups has been reached: B-cell lymphoma: unclassifiable with features intermediate between Diffuse Large B cell lymphoma and Burkitt Lymphoma ; c-MYC + Diffuse large B-cell lymphoma (DLBCL) and c-MYC+ plasmablastic lymphoma.
If questions arise related to diagnosis, please contact the National Cancer Institute (NCI) Principal Investigator, Dr. Mark Roschewski or the NCI study coordinator, A. Nicole Lucas.
EXCLUSION CRITERIA:
Primary purpose
Allocation
Interventional model
Masking
194 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal